An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)
Sponsor: Pfizer
Terminated
Study terminated on 7 April 2015 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Other terminated trials from Pfizer
Other Pulmonary Disease, Chronic Obstructive trials with similar outcome
This PHASE2 trial investigates Pulmonary Disease, Chronic Obstructive and is currently terminated or withdrawn. Pfizer leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .